Skye Bioscience, Inc.
SKYE
Rank in Stocks
#31472
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on... Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Share Price
$0.69
Last synced: 2026-11-09
Market Cap
$3.06M
Change (1 day)
-30.32%
Change (1 year)
-54.61%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Skye Bioscience, Inc. (SKYE)
Category
Healthcare
EPS for Skye Bioscience, Inc. (SKYE)
EPS as of June 2026 TTM: $-10.16
According to Skye Bioscience, Inc.'s latest financial reports, its current EPS (TTM) is $-10.16. At the end of 2025 the company had an EPS of $-11.28, a decrease compared to its 2024 EPS of $-5.84.
EPS history for Skye Bioscience, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-10.16 | -9.93% |
| 2025 | $-11.28 | 93.15% |
| 2024 | $-5.84 | -86.41% |
| 2023 | $-42.96 | -38.77% |
| 2022 | $-70.16 | 75.40% |
| 2021 | $-40.00 | -29.68% |
| 2020 | $-56.88 | -459.09% |
| 2019 | $15.84 | -105.42% |
| 2018 | $-292.08 | 42.51% |
| 2017 | $-204.96 | -38.90% |
| 2016 | $-335.44 | -41.32% |
| 2015 | $-571.60 | 9.79% |
| 2014 | $-520.64 | 1,748.86% |
| 2013 | $-28.16 | -2,807.69% |
| 2012 | $1.04 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -254.13% |
US
|
|
| $-7.07 | -30.41% |
US
|
|
| $-5.29 | -47.93% |
AU
|
|
| $12.88 | -226.77% |
BE
|
|
| $21.56 | -312.20% |
NL
|
Questions about Skye Bioscience, Inc.'s earnings per share (EPS)
What is Skye Bioscience, Inc.'s earnings per share (EPS)?
Skye Bioscience, Inc.'s earnings per share (EPS) over the last twelve months is $-10.16, as of Jun 2026.
What was Skye Bioscience, Inc.'s earnings per share (EPS) in 2025?
In 2025, Skye Bioscience, Inc.'s earnings per share (EPS) was $-11.28, compared with $-5.84 in 2024.
How has Skye Bioscience, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Skye Bioscience, Inc.'s earnings per share (EPS) was highest in 2024 ($-5.84) and lowest in 2022 ($-70.16).
How does Skye Bioscience, Inc.'s earnings per share (EPS) compare with similar companies?
Skye Bioscience, Inc.'s earnings per share (EPS) ($-10.16) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.